ALB and acute kidney injury: Evidence suggests that albumin-conjugated EVs exhibit an extended half-life [235], and albumin's renal tissue affinity facilitates uptake by TECs [236], thereby enhancing the therapeutic potential of albumin-bound EVs in cisplatin-induced AKI mouse models [237].